In recent years, China's new drug research and development situation has been gratifying and has entered a new stage. The continuous development and globalization of biotechnology and pharmaceutical innovation have put forward higher requirements for data innovation. This includes applying more innovative design and analysis methods to effectively assist in the design and decision-making of drug clinical development, and enhance the leadership of data science in drug development. At the same time, with China accession to ICH, statistical review is playing an increasingly important role in drug regulation, and while considering the current status of drug development in our country, it is rapidly aligning with international standards.

In 2023 DIA Quantitative Science Forum, experts, scholars and young workers from enterprises, academia and regulatory agencies in the field will continue to share and exchange relevant hot issues at home and abroad, and further explain how quantitative science can be used in play a greater role in drug development.

Main content

• E17 landing and global new drug development simultaneously

• The role of quantitative pharmacology in new drug development

• Application and latest developments of adaptive design in clinical trials

• Statistical considerations in combination therapy study design

• Design of early clinical trials

• Complex innovative experimental designs

• Statistical talent and leadership development

•     ……

  

TARGET AUDIENCE

      Statisticians and Other Data Scientists

• Clinicians

• Data Management Expert

• Regulatory Scientists

• Quantitative Science Experts in Academia

• Quantitative Science Specialists in Regulatory Agencies

Contact

DIA |  Email：China@diaglobal.org